Nektar Therapeutics prices $100M public offering at $23.50 per share

NEKTAR THERAPEUTICS

Nektar prices 4,255,320 shares at $23.50/share for gross proceeds of $100M.
Net proceeds estimated at $93.7M ($107.8M if underwriters' option exercised in full).
Offering expected to close July 2, 2025; Jefferies and Piper Sandler are joint bookrunners.
Proceeds to fund R&D, clinical development, manufacturing, and other general corporate purposes.
Underwriters have a 30-day option to purchase up to an additional 638,298 shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.